Global Urinary Incontinence Therapeutics Market Insights Forecasts to 2033 

• The Global Urinary Incontinence Therapeutics Market Size was Valued at USD 4.31 Billion in 2023
• The Market Size is Growing at a CAGR of 4.05% from 2023 to 2033 
• The Worldwide Urinary Incontinence Therapeutics Market Size is Expected to Reach USD 6.41 Billion by 2033 
• Europe is Expected to Grow the fastest during the forecast period.   

The Global Urinary Incontinence Therapeutics Market Size is anticipated to exceed USD 6.41 Billion by 2033, growing at a CAGR of 4.05% from 2023 to 2033.

Market Overview

The inadvertent passing of urine is known as urinary incontinence. Millions of people are said to be impacted by this widespread issue. Urinary incontinence comes in a variety of forms, such as: Urine leakage that occurs while your bladder is under pressure, such as when you cough or laugh, is known as stress incontinence. Additionally, a wide range of drugs, including topical estrogens, beta-3 adrenergic agonists, and anticholinergics, are sold in this market. By strengthening the urethral and vaginal tissues, decreasing bladder contractions, and improving bladder capacity, these medications aid in symptom management. The market is expanding because industry participants are consistently spending money on research and development to bring safer and more effective therapies. In addition, urine incontinence has become much more widely recognized and diagnosed in recent years. The reduction of the stigma attached to this illness and the encouragement of people to seek medical assistance have been greatly aided by health campaigns and educational initiatives by pharmaceutical firms and healthcare organizations.

Report Coverage

This research report categorizes the global urinary incontinence therapeutics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global urinary incontinence therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global urinary incontinence therapeutics market.  

Driving Factors

The market's growth is mostly being driven by the aging population. The number of aged people worldwide is growing as life expectancy rises, which raises the prevalence of age-related illnesses like UI. Due to weakening pelvic floor muscles, reduced bladder capacity, and other medical disorders that affect urine function, older persons frequently struggle with bladder control. This change in the population has a major impact on the rising need for treatment options to control and lessen these symptoms. Urinary incontinence is a prevalent issue that many people deal with. The American Urological Association estimates that between 25% and 33% of American men and women suffer from urine incontinence. Women experience urinary incontinence at a higher rate than males do. Compared to 1.5–5% of men, it is believed that 30% of women between the ages of 30 and 60 suffer from it. The notable rise in the population with urinary incontinence-related illnesses is propelling the market's expansion. Furthermore, the number of individuals in the world who are 60 years of age or older is expected to increase to 2.1 billion by 2050. Between 2020 and 2050, the population of people 80 years of age or older is predicted to treble, reaching 426 million. The burden of UI and other geriatric disorders, such as falls and delirium, is predicted to increase as the population ages. This rise calls for more affordable and efficient therapies, which is fueling this industry's research and development. As a result, medical professionals are concentrating on enhancing older individuals' quality of life by managing UI better.

Restraints & Challenges

The market for treatments for urine incontinence is hindered by a lack of knowledge about the latest developments in treatment choices and the potential side effects of utilizing these devices.

Market Segmentation

The global urinary incontinence therapeutics market share is classified into type and drug class.

• The stress segment is expected to hold the largest share of the global urinary incontinence therapeutics market during the forecast period.                                  

Based on the type, the global urinary incontinence therapeutics market is categorized as stress, urge, overflow, and functional incontinence. Among these, the stress segment is expected to hold the largest share of the global urinary incontinence therapeutics market during the forecast period. The growing number of older people and the high rate of stress incontinence in expectant and postpartum mothers are important contributing factors. This problem is exacerbated by the strain that pregnancy and childbirth place on the pelvic tissues. Improvements in diagnosis and awareness, together with new therapy choices, further propel market growth.

• The anticholinergics segment is expected to grow at the fastest CAGR during the forecast period.       

Based on the drug class, the global urinary incontinence therapeutics market is categorized as anticholinergics, beta-3 adrenoceptor agonists, alpha blockers, and estrogen. Among these, the anticholinergics segment is expected to grow at the fastest CAGR during the forecast period. Their ability to lessen bladder contractions, a crucial symptom of many forms of UI, is what is driving this increase. Their continued efficacy and safety in clinical trials supports their use as a mainstay of care.

Regional Segment Analysis of the Global Urinary Incontinence Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the global urinary incontinence therapeutics market over the forecast period.

North America is projected to hold the largest share of the global urinary incontinence therapeutics market over the forecast period. Market participants are actively working to fulfill the various demands of patients by creating novel treatments and enhancing current ones. In the US, regulatory agencies such as the FDA make sure that new products are thoroughly tested for safety and effectiveness before being allowed to enter the market. GEMTESA (vibegron) 75 mg Tablets, for example, were approved by the U.S. FDA in December 2020 for the treatment of people with overactive bladder (OAB). The beta-3 adrenergic receptor (β3) agonist GEMTESA is recommended for the treatment of urge urinary incontinence (UUI), urgency, and frequent urination that are linked with OAB.

Europe is expected to grow at the fastest CAGR growth of the global urinary incontinence therapeutics market during the forecast period. The market for treatments for urine incontinence is expanding significantly in Europe as a result of research and development initiatives aimed at reducing the prevalence of the condition, especially in nations like the UK, Sweden, and Germany.Over 3 million people in the UK suffer from urine incontinence, according to a report published in April 2024. These programs seek to improve patient outcomes and treatment efficacy, reflecting the region's increasing need for creative approaches to addressing this common ailment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global urinary incontinence therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• AbbVie Inc.
• Astellas Pharma Inc.
• Johnson & Johnson
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bayer AG
• Ferring Pharmaceuticals
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Key Market Developments

• In March 2024, the FDA has approved a supplemental new medication application for vibegron, according to Sumitomo Pharma America. This application is for approval to treat males with symptoms of an overactive bladder (OAB) who are currently receiving medication for benign prostatic hyperplasia (BPH).

Market Segment

• This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global urinary incontinence therapeutics market based on the below-mentioned segments: 

Global Urinary Incontinence Therapeutics Market, By Type

• Stress
• Urge
• Overflow
• Functional Incontinence

Global Urinary Incontinence Therapeutics Market, By Drug Class

• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen

Global Urinary Incontinence Therapeutics Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa